Complex Regional Pain Syndrome
The objective of this trial is to investigate the efficacy and safety of IV neridronic acid in subjects with Complex Regional Pain Syndrome (CRPS).
The trial consists of an Enrollment Period lasting up to 60 days, Treatment Period A consisting of 4 infusions (neridronic acid or placebo) over 10 days, and a Follow-up Period 1 until Week 26. Follow up can be up to 52 weeks.
- Informed consent signed.
- Male or female participant at least 18 years of age.
- A diagnosis of CRPS Signs and symptoms of CRPS must apply to an affected limb (arm or leg). The CRPS duration must be 2 years or less since onset of symptoms.
- Participants must have failed attempts with at least 2 available treatments for CRPS, 1 of which must have been a pharmacologic treatment.
- Women of child-bearing potential must have a negative urine pregnancy test.
The trial doctor will review other eligibility criteria with you. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03560986